Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides calories and serves as a source of glucose for cellular metabolism. Sodium chloride supplies electrolytes to maintain osmotic balance and fluid distribution.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Fluid and electrolyte replacement therapy,Treatment of dehydration,Maintenance of hydration and electrolyte balance,Provision of caloric support in parenteral nutrition
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion, rate depends on clinical condition; typical maintenance: 100-200 m L/hour for adults.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Glucose: ~1.5-2 hours (metabolic clearance); Sodium: biological half-life ~2-3 weeks (exchangeable pool); Chloride: ~12-24 hours (renal adaptation). Clinical context: Dextrose 2.5% provides ~85 kcal/L as glucose, rapidly cleared, while sodium and chloride are regulated by renal function and hormonal control.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Dextrose is metabolized via glycolysis to pyruvate, entering the Krebs cycle for energy production; regulated by insulin and other hormones. Sodium chloride is not metabolized; it dissociates into Na+ and Cl- ions and is excreted primarily by the kidneys.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal: Glucose is completely reabsorbed or metabolized; negligible excretion. Sodium and chloride are primarily excreted renally, with >90% reabsorption under normal conditions; excess is excreted in urine. Water follows solute excretion.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Glucose: <5% bound (non-specifically to albumin); Sodium and chloride: negligible (<1% bound).
Low protein binding; 0–11% bound, primarily to albumin.
Dextrose: ~0.2 L/kg (intracellular distribution); Sodium: ~0.2-0.3 L/kg (extracellular fluid); Chloride: ~0.2-0.3 L/kg (extracellular fluid). Values represent distribution into total body water.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
IV: 100% bioavailability for all components. Not administered via other routes.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
Anuria: contraindicated; severe impairment (e GFR <30 m L/min): use with caution and monitor fluid balance.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No dose adjustment recommended based on Child-Pugh score; monitor for fluid overload in cirrhosis.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Weight-based: 4-8 mg/kg/min dextrose as continuous infusion; adjust rate based on serum glucose and electrolytes.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Use with caution due to decreased renal function; reduce infusion rate and monitor for hyperglycemia and fluid overload.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to corn or corn products (dextrose derived from corn). Solutions containing sodium chloride should be used with caution in patients with congestive heart failure, severe renal insufficiency, or conditions involving sodium retention.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Use with caution in patients with hyperglycemia, diabetes mellitus, renal impairment, congestive heart failure, or conditions predisposing to fluid overload. Monitor serum glucose, electrolytes, and fluid balance. Avoid extravasation; may cause tissue necrosis.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hyperglycemia with severe dehydration,Intracranial or intraspinal hemorrhage,Known hypersensitivity to corn or corn products,Severe electrolyte disturbances,Anuria or severe renal impairment with oliguria
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No known food interactions. However, dietary sodium and glucose intake may need adjustment based on patient's condition.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
No known teratogenic risk in any trimester at physiologic concentrations. Dextrose and sodium chloride are essential nutrients and electrolytes; no human or animal studies indicate teratogenicity. However, hyperglycemia from excessive dextrose may cause fetal macrosomia, neonatal hypoglycemia, or other diabetic fetopathy if maternal glucose is poorly controlled. Use caution in gestational diabetes.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Compatible with breastfeeding. Dextrose and electrolytes are normal milk constituents; no adverse effects expected. M/P ratio not applicable/unknown as these are endogenous substances.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
No dose adjustment required under normal circumstances. Pregnancy increases plasma volume and glomerular filtration rate, but this does not necessitate dose change for isotonic/dextrose solutions as they are administered to maintain homeostasis. Monitor for fluid overload in preeclampsia or renal impairment. In gestational diabetes, dextrose infusion rate may need reduction and blood glucose monitoring.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
This solution provides 85 m Eq/L sodium and 77 m Eq/L chloride. It is isotonic (308 m Osm/L) and suitable for maintenance fluids in euvolemic patients. Monitor for hypernatremia in renal impairment. Use with caution in heart failure due to sodium load. Do not administer simultaneously with blood products via same line due to risk of hemolysis.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This solution contains dextrose (sugar) and salt, which may affect blood glucose and blood pressure.,Report any shortness of breath, swelling, or rapid weight gain as these may indicate fluid overload.,If diabetic, monitor blood glucose more frequently during infusion.,Notify your healthcare provider if you have a history of kidney disease or heart failure.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides calories and serves as a source of glucose for cellular metabolism. Sodium chloride supplies electrolytes to maintain osmotic balance and fluid distribution.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Intravenous infusion, rate depends on clinical condition; typical maintenance: 100-200 m L/hour for adults.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. No known teratogenic risk in any trimester at physiologic concentrations. Dextrose and sodium chloride are essential nutrients and electrolytes; no human or animal studies indicate. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.